21,23-Core-Modified Porphyrins as Sensitizers for Photodynamic Therapy

Photodynamic Therapy (PDT) is a unique approach to the treatment of cancer and other diseases. Able to differentiate cancerous and normal tissue while minimizing or eliminating many of the side effects associated with conventional chemotherapy and r adiation, PDT offers an appealing and cost-effective treatment alternative. Current limitations of PDT include depth of penetration, selectivity, and photosensitization. Researchers at the University at Buffalo have developed new compounds that overc ome some of these limitations and provide a number of additional advantages compared to current PDT compounds:

* The compounds are single, pure molecular composition
* Longer wavelength absorption maxima for greater penetration of light i nto tissue
* Higher extinction coefficients for better harvesting of light
* High uptake in cancer cells and malignant tissues
* High quantum yields tailored specific to the application in question (singlet oxygen in PDT applications, fl orescence in diagnostic applications)
* Lower therapeutic dose with a high therapeutic index
* High efficacy in vivo
* Rapid clearance from healthy cells and tissues
* Little or no long-term skin photosensitization
* No toxic morbidity or side effects in vivo

Categories: Sensors, Therapeutic and Vaccines Patents Issues: 6,984,656

Type of Offer: Licensing



Next Patent »
« More Pharmaceutical Patents

Share on      


CrowdSell Your Patent